FDA makes acting CDER, CBER chiefs permanent
Michael Davis becomes the permanent head of CDER, while Karim Mikhail is confirmed as permanent CBER director and the FDA names its first AI leader.
Newsletters and Deep Dive digital magazine
Michael Davis becomes the permanent head of CDER, while Karim Mikhail is confirmed as permanent CBER director and the FDA names its first AI leader.
The future of drug development is not scientists versus algorithms. It is scientists and algorithms working together.
Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.
Researchers in Türkiye have shown in a small clinical trial that laughter therapy can reduce breathing difficulties in COPD patients.
Novartis has suffered another pipeline blow, this time involving its highly anticipated neuromuscular disease therapy del-desiran.
Editor's Picks
Newsletters and Deep Dive
digital magazine